Biomarkers and Choroidal Neovascularization

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to find biomarkers in the blood and aqueous humor of patients with type 1 choroidal neovascularization and correlate them with the response to anti-VEGF treatment.

Detailed Description
-----------------
Age-related macular degeneration (AMD) is the most frequent cause of blindness in industrialized countries. Multiple molecular pathways have been implicated in the pathogenesis of choroidal neovascularization (CNV). Currently, the treatment relies on neutralization of VEGF (Vascular Endothelial Growth Factor). However some patients have an incomplete response to anti-VEGF treatment. A recent study suggested the implication of the mineralocorticoid receptor pathway in the formation of CNV. The study (of investigators) aim is to evaluate the concentation of metabolites of MR pathway in the blood and aqueous humor of patients with CNV and compared them with patients without CNV in order to increase our understanding of CNV pathogenesis and find potential biomarker of response to anti-VEGF treatment.

Official Title
-----------------
Biomarkers Analysis of Mineralocortoid Receptor Activation in the Serum and Ocular Fluid of Patients With Choroidal Neovascularization

Conditions
-----------------
Choroidal Neovascularization, Mineralocorticoid Excess

Intervention / Treatment
-----------------
* Other: Blood and aqueous humor biomarker of treatment response


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients of group 1: Patients with type 1 choroidal neovascularization in a context of central serous chorioretinoathy or age related macular degeneration Patients without intravitreal injection or last intravitreal injection > 3 months Informed signed consent Patients of group 2: Patients without choroidal neovascularization Patients with intraocular surgery (cataract or vitrectomy surgery) Signed consent Exclusion Criteria: Myocardial infarction < 12 months Chronic renal failure Inflammatory disease Infectious disease :HIV, viral hepatitis, tuberculosis Type 1 or 2 Diabetes Patients treated by mineralocorticoid antagonist treatment. Type 2 or 3 choroidal neovascularization Pregnant woman

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br>Patients with choroidal neovascularization in the context of age-related macular degeneration or central serous chorioretinopathy | Other: Blood and aqueous humor biomarker of treatment response<br>* Blood analyses and aqueous humor analysis<br>|
| Group 2<br>Control group : patients without choroidal neovascularization | Other: Blood and aqueous humor biomarker of treatment response<br>* Blood analyses and aqueous humor analysis<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| biomarker analysis in blood and aqueous humor of patients with neovascularization and controls | Biomarker concentrations (pg/ml) will be evaluated with ELISA (Enzyme Linked ImmunoSorbent Assay). | 24 months | 
| biomarker analysis in blood and aqueous humor of patients with neovascularization and controls | Biomarker concentrations (pg/ml) will be evaluated with Mulitplex Biorad. | 24 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| biomarkers and treatment response | Correlation between biomarker level and the response to anti-VEGF treatment | 24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
central serous chorioretinopathy, age related macular degeneration, biomarker